Merck Appeals Potentially Costly NJ Class ActionHealth & Wellness  - 618 days ago - reuters.com March 19 (Reuters) - Merck & Co. (MRK.N: Quote, Profile, Research) made its latest case on Monday to decertify a class-action lawsuit involving pain drug Vioxx, which opposition attorneys said could cost the drugmaker up to $27 billion.
|
|
||||||||
|
Login to leave a comment
Or, log in with your
Facebook account: |
||||||||
Loading Noted By...Please Wait
Most Active Today in Health & Wellness
|
|
's contributions:
|
|||
